<a href="https://laohu8.com/S/LYEL">Lyell Immunopharma</a> Acquires Global Rights to Next-Generation CAR T-Cell Therapy for Colorectal Cancer
Lyell Immunopharma has acquired exclusive global rights, outside of mainland China, Hong Kong, Macau, and Taiwan, to LYL273, a next-generation CAR T-cell product candidate targeting metastatic colorectal cancer. LYL273, which is currently in a U.S. Phase 1 clinical trial, has shown a 67% overall response rate and an 83% disease control rate at its highest dose, along with a manageable safety profile in patients with refractory metastatic colorectal cancer. Under the agreement, Lyell will make a $40 million upfront payment and issue 1.9 million shares of its common stock to ICT, the original developer. ICT is also eligible for additional milestone payments, further equity, and tiered royalties on future sales. Lyell expects the transaction to have a modest impact on 2025 operating expenses and projects cash reserves to fund operations into 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lyell Immunopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572064-en) on November 10, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.